OKLAHOMA
Health Care Authority

State of Oklahoma
SoonerCare
Tagrisso® (Osimertinib) Prior Authorization Form

Member Name:**______________________** ***Date of Birth:*****____________** ***Member ID#:*****___________________**

Drug Information

Pharmacy billing (NDC:_______________________) Start Date (or date of next dose):_________________

Dose:***______________________________*** ***Dosing Regimen:*****____________________________________**

Pharmacy Information

Pharmacy NPI:**____________________________** ***Pharmacy Name:*****________________________________**

Pharmacy Phone:**________________________** ***Pharmacy Fax:*****___________________________________**

Prescriber Information

Prescriber NPI:**______________________** ***Prescriber Name:*****______________________________________**

Prescriber Phone:**_______________** ***Prescriber Fax:*****_______________** ***Specialty:*****_____________________**

Criteria

For Initial Authorization (Initial approval will be for the duration of 6 months):

1. Please indicate diagnosis and information:
   - ❑ **Non-Small Cell Lung Cancer (NSCLC)**
     - A. Is diagnosis non-metastatic NSCLC? Yes____ No____
       - i. Will osimertinib be used as adjuvant therapy following tumor resection? Yes____ No____
       - ii. Is disease epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R mutation positive? Yes____ No____
     - B. Is diagnosis metastatic NSCLC? Yes____ No____
       - i. Is disease EGFR T790M mutation-positive? Yes___ No___
       - ii. Is disease EGFR exon 19 deletion or exon 21 L858R mutation positive? Yes____ No____
     - C. Is diagnosis locally advanced or metastatic non-squamous NSCLC? Yes____ No____
       - i. Will osimertinib be used as first-line treatment? Yes____ No____
       - ii. Is disease EGFR exon 19 deletion or exon 21 L858R mutation positive? Yes____ No____
       - iii. Will osimertinib be used in combination with pemetrexed and platinum-based (cisplatin or carboplatin) chemotherapy? Yes____ No____
     - D. Will osimertinib be used as a single agent? Yes____ No____
   - ❑ **If diagnosis is not listed above, please provide diagnosis:__________________________**

Additional Information:____

For Continued Authorization:

1. Date of last dose:____________________
2. Does member have any evidence of progressive disease while on osimertinib? Yes____ No____
3. Has the member experienced adverse drug reactions related to osimertinib therapy? Yes____ No____

*If yes, please specify adverse reactions:*____

Additional Information:____

Prescriber Signature: ______________________________ **Date:_____________________________**

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. *Failure to complete this form in full will result in processing delays.*

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:	CONFIDENTIALITY NOTICE
University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4	*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*